Aptevo Therapeutics, Inc. (APVO)

Aptevo Therapeutics' stock price has been impacted by several events over the past six months. Positive interim results from the Phase 1b/2 clinical trial of mipletamig for AML and MDS have been reported. Executive leadership transitions were announced to support the company's next phase of growth. The company provided its 2025 financial results and business updates. The company's stock slumped after a one-for-eighteen reverse stock split was approved. Aptevo's stock rallied on a $2.1 million registered direct offering and warrant sale. Aptevo Therapeutics has been upgraded to a Zacks Rank #2 (Buy). The share price as of May 5, 2026, was $5.35, representing a decline of 31.32% over the past year.

Aptevo Therapeutics Inc. does not experience traditional demand seasonality for its products and services. The company's revenue and financial performance are primarily driven by research and development milestones, progress in clinical trials, potential future licensing agreements, and eventual drug commercialization.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapeutic candidates for cancer treatment. The company utilizes its ADAPTIR™ and ADAPTIR-FLEX™ modular protein platform technologies to create bispecific and multi-specific antibody-based therapeutics. Its major product candidates include Mipletamig, a bispecific antibody targeting CD123 and CD3 in Phase 1b/2 clinical trials for AML and MDS; ALG.APV-527, a bispecific antibody targeting 4-1BB and tumor-associated antigens in Phase 1 clinical trials for various solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology; APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer; APVO455, designed to avoid activating T cells in the periphery and engage them only in the presence of Nectin-4-positive tumor cells; APVO451, a trispecific ADAPTIR-FLEX candidate targeting Nectin-4, CD3, and CD40; and APVO452, a trispecific candidate targeting PSMA, CD3, and CD40.

Aptevo Therapeutics Inc. is headquartered in Seattle, Washington, and was incorporated in Delaware in 2016 as a spin-off from Emergent BioSolutions Inc. The company focuses on developing immunotherapeutic candidates for cancer treatment in the United States.

Aptevo Therapeutics' brand reputation has been influenced by its clinical development progress, particularly the positive interim results from the Phase 1b/2 clinical trial of mipletamig. The expansion of its CD3 pipeline and the introduction of its first trispecific drug candidates also contribute to a reputation for innovation in immuno-oncology. While the stock price has seen a decline and a reverse stock split occurred, the focus on positive clinical trial results and pipeline expansion has been a key driver of its scientific standing.

The ownership structure of Aptevo Therapeutics is a mix of institutional, retail, and individual investors. Approximately 1.89% to 4.47% of the company's stock is owned by institutional investors. Approximately 1.15% of the company's stock is held by insiders. Approximately 95.89% is owned by public companies and individual investors (retail investors).